Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Cream

Transatlantic Co-Operation Leads To Major Scientific CMOS (sCMOS) Technology Breakthrough
CMOS image sensor (CIS) technology stands on the brink of fulfilling its potential to become the global detector platform of choice for scientific photonics applications that require world class performance in the fields of sensitivity, speed, dynamic range, resolution, and field of view.
generic viagra online
Classification Methods For Identifying The Neural Characterics Of Antidepressant Treatment
Depression is a major public health problem, and one of the most important challenges for psychiatrists is to determine whether an individual with depression should receive cognitive-behavioral therapy or treatment with antidepressant medication. A study by researchers from Emory University, presented at the Annual Meeting of the Organization for Human Brain Mapping in San Francisco, used brain imaging along with sophisticated statistical techniques to examine the differences in brain function that result from these two different kinds of treatment. Forty individuals with depression were scanned with magnetic resonance imaging after undergoing cognitive behavioral therapy or antidepressant therapy. The researchers found that they could distinguish the brain activity of individuals undergoing the two different treatments, and in particular that the two treatments differently affected the communication of the brain areas that are thought to play a role in depression, including the communication between the prefrontal cortex and the nucleus accumbens, and between the subgenual cingulate and the thalamus. The results provide a basis for future research that will try to predict which individuals will benefit from different treatments for depression. Drugshop to buy zoloft online and other pills.
News of the day
Senate Judiciary Committee Vote Clears Way For Confirmation Of Supreme Court Nominee Sotomayor
The Senate Judiciary Committee"s approval on Tuesday of Supreme Court nominee Sonia Sotomayor "cleared the way" for a vote next week in the full Senate, where she is expected to be confirmed, the New York Times reports. The committee"s 12 Democrats voted in favor of Sotomayor, with one Republican -- Sen. Lindsey Graham (S.C.) -- joining them in the 13-6 vote (Lewis, New York Times, 7/28). According to Roll Call, Sotomayor"s confirmation is not in doubt, as members of both parties have predicted as many as 70 votes in her favor. So far, five GOP senators have said they will support the nomination, including Graham, Susan Collins (Maine), Richard Lugar (Ind.), Mel Martinez (Fla.) and Olympia Snowe (Maine) (Stanton, Roll Call, 7/29). Strategists on both sides who have been following the nomination said that as many as five more Republicans could announce intentions to vote for Sotomayor, the AP/San Francisco Chronicle reports (Hirschfeld Davis, AP/San Francisco Chronicle, 7/29). According to the Chicago Tribune, other Republicans initially appeared open to supporting Sotomayor, but pressure from antiabortion-rights groups and gun-rights advocates has swayed them in the other direction (Savage/Simon, Chicago Tribune, 7/29).The Times reports that Tuesday"s partisan vote indicates that Senate Republicans are "determined to deny ... an easy path" for President Obama in his nominations to fill the dozens of open federal appeals courts seats and any future Supreme Court vacancies. Obama is expected to announce several appeals court nominees in the coming weeks. On some appeals courts, including the Richmond, Va.-based Fourth Circuit, Obama"s nominations could change the ideological balance on the bench (New York Times, 7/28).According to the Tribune, Republicans believe that their strategy in Sotomayor"s confirmation hearings "succeeded in setting a new, conservative standard for judging." Throughout the hearings, Democrats portrayed Sotomayor as a moderate, cautious jurist, while many Republican senators sought to portray her as an activist judge. Sen. Jeff Sessions (Ala.), the Senate Judiciary Committee"s ranking Republican, said that the confirmation process has been a "repudiation of activist legal thought" and that it "will now be harder to nominate activist judges" (Chicago Tribune, 7/29). Committee member John Cornyn (R-Texas), who serves as the chair of the National Republican Senatorial Committee, said he hopes Sotomayor"s hearings serve as an example for future judicial nomination debates. He added that the Republicans on the committee have "made clear that radical views on judging have no place on the federal bench. And we have set expectations for future nominees." Senate Majority Leader Harry Reid (D-Nev.) on Tuesday said that he intends to bring Sotomayor"s nomination to a full Senate vote prior to Congress" August recess. He has not said what day the debate is scheduled to begin or how many days are scheduled, although he noted that debate could take several days (Roll Call, 7/29).
Mental Health

St Gallen Consensus 2009: A Radically Different Approach To Treating Early Breast Cancer

A radically different approach to choosing the best treatment options for early breast cancer has been proposed by an international panel of experts in a report from the 11th St Gallen conference. The report is published online in the cancer journal, Annals of Oncology [1] , and represents the consensus on early breast cancer treatment that emerged from the conference of more than 4,800 participants from 101 countries, which took place in March 2009. The authors expect the consensus report to change clinical practice. While it continues to recognise that early breast cancer is a heterogeneous disease and that patients should receive personalised care targeted at their particular type of disease, the report proposes a different way of assessing the disease, its risk and the appropriate treatment. The authors write: "In distilling patient and tumour features to reach patient treatment decisions, the panel has adopted a fundamentally different approach from that used in previous consensus reports. Clinical decisions in systemic adjuvant therapy of early breast cancer must address three distinct questions: (i) what justifies the use of endocrine therapy, (ii) what justifies the use of anti-HER2 therapy, and (iii) what justifies the use of chemotherapy. Because these decisions are based on quite separate criteria, the previous attempt to produce a single-risk categorization and a separate therapy recommendation are no longer considered appropriate." The authors then give a new algorithm for clinicians to use when deciding on the best treatment approach for each patient. One of the authors, Professor Richard Gelber (Professor in Biostatistics at Harvard University and Dana-Farber Cancer Institute, Boston, MA, USA and Director of the Statistical Center, International Breast Cancer Study Group), said: "This consensus is important because it provides solutions to open questions in controversial areas concerning treatment of women with early breast cancer. While the 2009 consensus maintains an emphasis on targeting adjuvant systemic therapies according to subgroups defined by predictive markers, it further refines the treatment algorithm by identifying "thresholds for indication" of each type of systemic treatment modality (endocrine therapy, anti-HER2 therapy, chemotherapy) based on criteria specific to each modality. We expect the refined algorithm to change clinical practice because it clarifies the indications for each treatment modality available today." Early breast cancer is defined as breast cancer that is confined to the breast, with or without axillary lymph node involvement, and which is easily removable by surgery. However, there are many different types, some of which carry a much higher risk of recurrence and metastases than others. Therefore, the report emphasises the importance of identifying which type of breast cancer a patient has and which treatment, or combination of treatments, are most likely to be successful. For instance, the panel recommends the inclusion of adjuvant endocrine therapy for most patients whose tumours show evidence of any detectable oestrogen receptor. Anti-HER2 therapy such as trastuzumab (Herceptin) is recommended for almost all patients with HER2-positive disease. The indication for use of adjuvant chemotherapy is more complex. Chemotherapy should be the mainstay of treatment for patients with triple-negative disease and conventionally is used before or concurrently with trastuzumab for patients with HER2 positive disease, while its use is less clear-cut for patients with ER-positive, HER2-negative disease. The increasing use of genetic profiling using microarrays (gene chip technology) is expected to help in such cases where treatment decisions are more difficult. Another of the authors, Professor Aron Goldhirsch (Professor of Medical Oncology, Director of the Department of Medicine, European Institute of Oncology, Milan, Italy, and Co-Chair of the Scientific Committee, International Breast Cancer Study Group), said: "High quality pathological work up has been recognized as essential to define the biological characteristics of the disease, especially in terms of markers of responsiveness to various treatments. Modern multi-gene arrays, if readily available, might be increasingly useful in defining features of prognosis and responsiveness and require further validation." The panel highlighted the importance of clinical trials. "Randomized clinical trials provide essential information on the safety and efficacy of treatments, but generally do not provide information about how best to care for individual patients. Therefore, a paramount role for the consensus panel was to identify areas of controversy, providing solutions for questions which have not yet been answered by randomized clinical trials," said Prof Gelber. A third author, Professor Alan Coates (Clinical Professor at the School of Public Health, University of Sydney, Sydney, New South Wales, Australia and Co-Chair of the Scientific Committee, International Breast Cancer Study Group) said: "The panel recognized and endorsed the refinement of surgery so that it is aimed at treating the tumour only, while preserving normal tissue as much as possible." The authors believe that the patient should be at the centre of all treatment decisions. "We recognize the importance of quality of life, supportive care and patient preference in the treatment decision-making process," said Prof Coates. 1] Citation: "Threshold for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009." Annals of Oncology. doi:10.1093/annonc/mdp322 Annals of Oncology


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009